References
-
1
Chong S A, Tan C H, Lee H S.
Worsening of psychosis with clozapine and selective serotonin reuptake inhibitor combination: two case reports.
J Clin Psychopharmacol.
1997;
17
68-69
-
2
Croissant B, Hermann D, Olbrich R.
Einspareffekte bei der Clozapin-Dosierung.
Psychopharmakotherapie.
2001;
8
128-130
-
3
Glass I B.
Alcohol hallucinosis: a psychiatric enigma - 2. Follow-up studies.
Br J Addict.
1989;
84
151-64
-
4
Koe B K, Weisman A, Welch W M, Brown R G.
Sertraline, 1S, 4S-N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthyline, a new uptake inhibitor with selectivity for serotonin.
J Pharamcol Exp Ther.
1983;
230
94-102
-
5
Mann K, Bartels M, Bauer H.
Amisulpride - An open clinical study of a new benzamide in schizophrenic patients.
Pharmacopsychiatry.
1984;
17
111-115
-
6
Martin P, Waters N, Schmidt C J, Carlsson A, Carlsson M L.
Rodent data and general hypothesis: antipsychotic action exerted through 5-HT2A receptor antagonism is dependent on increased serotonergic tone.
J Neural Transm.
1998;
105
365-396
-
7
Neiman J, Litton J E.
Reduced [11C]flumazenil radioligand binding in the thalamus in alcoholics.
Addict Biol.
2000;
5
97-99
-
8
Nyberg S, Eriksson B, Oxenstierna G, Halldin C, Farde L.
Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HAT2A receptor occupancy in schizophrenic patients.
Am J Psychiat.
1999;
156
869-875
-
9
Popli A P, Fuller M A, Jaskiw G E.
Sertraline and psychotic symptoms: A case series.
Ann Clin Psychiat.
1997;
9
15-17
-
10
Schmidt C J, Sorensen S M, Kehne J H, Carr A A, Palfreyman M G.
The role of 5-HT2A receptors in antipsychotic activity.
Life Sci.
1995;
56
2209-2222
-
11
Silver H, Jahjah N, Kushnir M.
Psychotic symptoms in schizophrenics during chronic fluvoxamine treatement. A report of two cases.
Schizophr Res.
1995;
16
77-79
-
12
Soyka M, Wegner U, Moeller H J.
Risperidone in treatment-refractory chronic alcohol hallucinosis.
Pharmacopsychiatry.
1997;
30
35-136
-
13
Soyka M.
Alcohol-induced hallucinosis. Clinical aspects, pathophysiology and therapy.
Nervenarzt.
1996;
67
891-895
-
14
Soyka M, Dresel S, Horak M, Rüther T, Tatsch K.
PET and SPECT findings in alcohol hallucinosis: case report and super-brief review of the pathophysiology of this syndrome.
W J Biol Psychiat.
2000;
1
215-218
-
15
Sproule B A, Otton S V, Cheung S W, Zhong X H, Romach M K, Seller E M.
CYP2D6 inhibition in patients treated with sertraline.
J Clin Psychopharmacol.
1997;
17
102-106
-
16
Surawicz F G.
Alcohol hallucinosis: a missed diagnosis.
Can J Psychiat.
1980;
25
57-63
-
17
Tsuang J W, Irwin M R, Smith T L, Schuckit M A.
Characteristics of men with alcoholic hallucinosis.
Addiction.
1994;
89
3-78
-
18
Wiesbeck G A, Weijers H G, Lesch O M, Glaser T, Toennes P J, Boening J.
Flupenthixol decanoate and relapse prevention in alcoholics: results from a placebo-controlled study.
Alcohol.
2001;
36
29-334
-
19
Yasui-Furkori N, Hidestrand M, Spina E, Facciola G, Scordo M G, Tybring G.
Different enantioselective 9-hydroxylation of risperidone by two human CYP2D6 and CYP3A4 enzymes.
Drug Metab Dispos.
2001;
29
1263-1268
Derik Hermann, M.D.
Central Institute of Mental Health
J5, 68159 Mannheim
Germany
Phone: +49-621-1703-0
Fax: +49-621-23429
Email: hermann@zi-mannheim.de
